Ovarian cancer clinical presentation

A 36-year-old woman who has been in good health presents to your clinic complaining of constipation and abdominal pain. She explains to you that she has been feeling stressed lately because her 40-year-old sister is undergoing chemotherapy for breast cancer, and they just lost there mother to ovarian cancer a few years ago. 

Although there have been some efforts to combine chemotherapy and radiation for patients with ovarian cancer, these cancers are usually advanced at presentation, limiting the role of local treatment. For patients with endometrial cancer, the possible role of combined adjuvant treatment is just beginning to be explored by the multi-institutional clinical trials groups. 

Cytotoxicity. JM216 was evaluated in vitro using the sulforhodamine B (SRB) assay against a panel of human ovarian carcinoma cell lines, established to be representative of the range of clinical responsiveness to platinum-based chemotherapy observed in patients presenting with advanced ovarian cancer (see below) [30]. JM216 showed a similar in vitro potency to that of cisplatin itself mean /C50 values across the ovarian cell line pan-... 

Paraneoplastic autonomic neuropathy is primarily seen with SCLC [103]. Lymphoma, non-small cell lung cancer, and ovarian cancer are also associated with autonomic disturbances [104]. Autonomic dysfunction affects 23-30% of Hu antibody positive patients [36, 98] and is the predominant symptom at presentation in up to 9% of the patients [90]. The onset of symptoms is usually subacute. A prominent clinical manifestation in patients with paraneoplastic autonomic neuropathy is gastrointestinal dysmotility and intestinal pseudo-obstruction, which can occur as part of the PEM/SN syndrome or as the sole symptom of Hu antibody related PNS. Ortostatic hypotension and erectile dysfunction are other common features [37, 105, 106], Autonomic neuropathy is also commonly associated with the CRMP-5 antibody and have been detected in more than 30% of CRMP-5 antibody positive patients [30], Inflammation in autonomic ganglia and infiltration of B and T cells have been demonstrated at autopsy [107], and Hu antibodies have been shown to induce neuronal apoptosis in cultured myenteric neurons [105],... 

Goff BA, Mandel LS, Melancon CH, Mrmtz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004 291 2705-2712. 

Because of the insidious onset and progression of ovarian cancer, an early diagnosis is very difficult. Moreover, accurate monitoring of tumor status is also difficult because patients are often in clinical remission when subclinical disease is present. 

In the present chapter, we have explained the beneficial role of trabectedin treatment against ovarian cancer s and we have shown its manageable adverse effects. We have concluded that compared to the significant risks of recurrence and resistance of ovarian cancer to the available therapeutic strategies, trabectedin can be used as an alternative therapeutic method. Moreover, there are numerous clinical studies on the efficacy and side effects of trabectedin and, therefore, we can easily take a decision about its most effective doses needed for obtaining anticancer effects. To conclude, it seems that transcription -coupled nucleotide excision repair mechanism plays a pivotal role in the anticancer effects of trabectedin. 

Ovarian cancer accounts for 4% of cancers in women and is responsible for 5% of cancer deaths [2]. In most Western countries, ovarian cancer is the sixth most common cancer in women, and the most lethal among the gynecological cancers. The incidence of ovarian cancer has increased by 30% over the past decade, while death from ovarian cancer has increased by 18% [3]. It is estimated that one women in 70 will develop ovarian cancer, and one woman in 100 will die of the disease. Ovarian cancer is usually clinically silent and about 75% of women present with advanced stages. This is why, despite developments in diagnosis and treatment, the overall survival rate has changed only Uttle wifliin the last decade [4]. Although there is an... 

Endometriomas may sometimes display similar imaging characteristics with a thick rim however, the clinical background is different. Ovarian cancer and especially metastases often present also as multiseptate ovarian masses. In ovarian cancers, well-enhanced septa and solid intralesional compo-... 

---